AbbVie has entered into a definitive agreement to acquire Apogee Therapeutics, a clinical-stage biotechnology company, in an all-cash transaction valued at approximately $10.9 billion. This acquisition aims to strengthen AbbVie's immunology portfolio with a pipeline of treatments for inflammatory diseases, including atopic dermatitis and asthma.
Key Details
- Transaction Terms: The deal is valued at approximately $10.9 billion in total equity, with AbbVie acquiring all outstanding shares of Apogee for $135.11 per share in cash.
- Strategic Assets: The acquisition includes Apogee's lead asset, zumilokibart (APG777), a late-stage monoclonal antibody for atopic dermatitis, and APG273, a combination therapy being developed for asthma.
- Timeline & Financials: The transaction is expected to close in the third quarter of 2026. AbbVie expects the deal to be accretive to its adjusted diluted earnings per share (EPS) beginning in 2032.